glp-1 research How RWD is transforming Targeting GLP-1, GIP & GCG

This product is supplied for research purposes only and is not offered for human or veterinary use

All skin types (Patch test recommended)

In this blog, well explore the battle of Tesamorelin vs

* Correspondence: Xin Xu, [email protected] ORCID: Xin Xu, orcid.org/0000-0002-7216-3787 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

For extended periods, storage at 20 C is recommended

2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)